Shanghai Wennai Pharmaceutical Technology Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute and chronic pain.

Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter ...

As part of a U.S. government-wide reduction in force aimed at restructuring and streamlining federal agencies, 5,200 Health ...

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...

After withdrawing plans for an IPO last year, Orum Therapeutics Inc. made its debut on the Korea Exchange in 2025 with a ₩50 ...

Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer management. However, acquired resistance and response variability point to rational combination strategies as the goal ...

Germitec SA raised $30 million in a series B financing round to bring Chronos, its chemical-free, ultraviolet-C (UV-C)-based disinfection system for ultrasound probes, to the U.S. market.

Urachal carcinoma is a rare cancer which lacks a standard drug therapy, and for which knowledge regarding its ...

Solid tumors are difficult to treat due to their heterogeneity and limited blood supply, which restrict the effective ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal ...

Med-tech M&As saw a strong start in January, totaling $4.51 billion, a significant jump from $18 million in December 2024 but lower than November’s $12.68 billion. Dealmaking reached $57.94 billion in ...

A second pentavalent vaccine for preventing meningococcal disease has been approved by the U.S. FDA. GSL plc’s Penmenvy will now go up against Pfizer Inc.’s Penbraya, which had a two-year head start ...